Peter Lamb's Insider Trades & SAST Disclosures
Peter Lamb's most recent trade in Exelixis Inc was a trade of 7,177 Common Stock done at an average price of $16.7 . Disclosure was reported to the exchange on Nov. 15, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Peter Lamb.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.71 per share. | 15 Nov 2022 | 7,177 | 410,958 (0%) | 0% | 16.7 | 119,928 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.08 per share. | 15 May 2022 | 6,123 | 396,362 (0%) | 0% | 20.1 | 122,950 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 59,490 | 402,485 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.59 per share. | 15 Feb 2022 | 17,651 | 342,995 (0%) | 0% | 18.6 | 328,132 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.59 per share. | 15 Feb 2022 | 2,526 | 360,646 (0%) | 0% | 18.6 | 46,958 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.10 per share. | 15 Nov 2021 | 53,022 | 349,077 (0%) | 0% | 18.1 | 959,698 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Sale of securities on an exchange or to another person at price $ 18.09 per share. | 15 Nov 2021 | 47,500 | 411,240 (0%) | 0% | 18.1 | 859,275 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 47,500 | 47,500 | - | - | Option (right to buy) | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.21 per share. | 15 Nov 2021 | 47,500 | 458,740 (0%) | 0% | 6.2 | 294,975 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.10 per share. | 15 Nov 2021 | 6,818 | 404,422 (0%) | 0% | 18.1 | 123,406 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.10 per share. | 15 Nov 2021 | 2,323 | 402,099 (0%) | 0% | 18.1 | 42,046 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 28,950 | 418,417 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.63 per share. | 30 Sep 2021 | 7,177 | 411,240 (0%) | 0% | 20.6 | 148,062 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2021 | 55,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.90 per share. | 16 Aug 2021 | 55,000 | 444,467 (0%) | 0% | 1.9 | 104,500 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Sale of securities on an exchange or to another person at price $ 18.44 per share. | 16 Aug 2021 | 55,000 | 389,467 (0%) | 0% | 18.4 | 1,014,200 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Sale of securities on an exchange or to another person at price $ 22.18 per share. | 17 Jun 2021 | 60,000 | 389,467 (0%) | 0% | 22.2 | 1,330,800 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 60,000 | 115,000 | - | - | Option (right to buy) | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.90 per share. | 17 Jun 2021 | 60,000 | 449,467 (0%) | 0% | 1.9 | 114,000 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 49,395 | 389,467 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Sale of securities on an exchange or to another person at price $ 22.11 per share. | 01 Mar 2021 | 65,000 | 340,072 (0%) | 0% | 22.1 | 1,437,150 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 65,000 | 60,000 | - | - | Option (right to buy) | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.70 per share. | 01 Mar 2021 | 65,000 | 405,072 (0%) | 0% | 1.7 | 110,500 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.91 per share. | 15 Feb 2021 | 3,718 | 340,072 (0%) | 0% | 21.9 | 81,461 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 71,293 | 363,787 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.56 per share. | 03 Feb 2021 | 19,997 | 343,790 (0%) | 0% | 22.6 | 451,132 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 9,370 | 292,494 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.70 per share. | 01 Feb 2021 | 65,000 | 348,124 (0%) | 0% | 1.7 | 110,500 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 65,000 | 125,000 | - | - | Option (right to buy) | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Sale of securities on an exchange or to another person at price $ 22.08 per share. | 01 Feb 2021 | 65,000 | 283,124 (0%) | 0% | 22.1 | 1,435,200 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.70 per share. | 04 Jan 2021 | 65,000 | 348,124 (0%) | 0% | 1.7 | 110,500 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 65,000 | 190,000 | - | - | Option (right to buy) | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Sale of securities on an exchange or to another person at price $ 20.32 per share. | 04 Jan 2021 | 65,000 | 283,124 (0%) | 0% | 20.3 | 1,320,800 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 65,000 | 255,000 | - | - | Option (right to buy) | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.70 per share. | 18 Dec 2020 | 65,000 | 348,124 (0%) | 0% | 1.7 | 110,500 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 18 Dec 2020 | 65,000 | 283,124 (0%) | 0% | 20.0 | 1,300,650 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.16 per share. | 15 Nov 2020 | 6,818 | 285,138 (0%) | 0% | 20.2 | 137,451 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.16 per share. | 15 Nov 2020 | 2,479 | 291,956 (0%) | 0% | 20.2 | 49,977 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.16 per share. | 15 Nov 2020 | 2,014 | 283,124 (0%) | 0% | 20.2 | 40,602 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Oct 2020 | 213,879 | 347,457 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.79 per share. | 22 Oct 2020 | 53,022 | 294,435 (0%) | 0% | 21.8 | 1,155,349 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2020 | 9,370 | 135,901 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.58 per share. | 02 Sep 2020 | 2,323 | 133,578 (0%) | 0% | 21.6 | 50,130 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Sale of securities on an exchange or to another person at price $ 22.56 per share. | 08 Jun 2020 | 26,000 | 126,531 (0%) | 0% | 22.6 | 586,560 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2020 | 26,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.51 per share. | 08 Jun 2020 | 26,000 | 152,531 (0%) | 0% | 5.5 | 143,260 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Sale of securities on an exchange or to another person at price $ 25.54 per share. | 07 May 2020 | 50,000 | 126,531 (0%) | 0% | 25.5 | 1,277,000 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2020 | 50,000 | 26,000 | - | - | Option (right to buy) | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.51 per share. | 07 May 2020 | 50,000 | 176,531 (0%) | 0% | 5.5 | 275,500 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2020 | 50,000 | 76,000 | - | - | Option (right to buy) | |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Sale of securities on an exchange or to another person at price $ 17.26 per share. | 06 Apr 2020 | 50,000 | 126,531 (0%) | 0% | 17.3 | 863,000 | Common Stock |
| Exelixis Inc | Peter Lamb | EVP, Scientific Strategy & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.51 per share. | 06 Apr 2020 | 50,000 | 176,531 (0%) | 0% | 5.5 | 275,500 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges